Search research articles
Contact Us
Filters
Showing results (91-100 of 136) with videos related to
Page
of 14
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Oncology and Therapy
|
October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Balazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
Lung Cancer (Auckland, N.Z.)
|
May 6, 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors
Alexa B Schrock, Russell Madison, Mark Rosenzweig, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD
Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
Cancer Discovery
|
October 1, 2013
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors
Nadine S Jahchan, Joel T Dudley, Pawel K Mazur, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 136) with videos related to
Sort By:
Page
of 14
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 26, 2023
Phase II Study of Docetaxel and Trametinib in Patients with KRAS Mutation Positive Recurrent Non-Small Cell Lung Cancer (NSCLC; SWOG S1507, NCT-02642042)
Shirish M Gadgeel, Jieling Miao, Jonathan W Riess, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 14, 2019
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating <i>RET</i> Alterations and Oncogenic Signaling Pathway Aberrations
Thereasa A Rich, Karen L Reckamp, Young Kwang Chae, et al.
Journal for Immunotherapy of Cancer
|
June 1, 2022
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
Miguel Lopez de Rodas, Venkata Nagineni, Arvind Ravi, et al.
Oncology and Therapy
|
October 11, 2025
The Phase 2b COPERNICUS Study of Subcutaneous Amivantamab with Lazertinib as First-Line Treatment, or with Chemotherapy as Second-Line Treatment, for EGFR-Mutated Non-Small Cell Lung Cancer: a Vodcast
Balazs Halmos, Narjust Florez, Sarah Goldberg, et al.
Lung Cancer (Amsterdam, Netherlands)
|
March 8, 2022
Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)
Benjamin Levy, Fabrice Barlesi, Luis Paz-Ares, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy
Jacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
Lung Cancer (Auckland, N.Z.)
|
May 6, 2020
Patients with NSCLCs Harboring Internal Inversions or Deletion Rearrangements of the <i>ALK</i> Gene Have Durable Responses to ALK Kinase Inhibitors
Alexa B Schrock, Russell Madison, Mark Rosenzweig, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 27, 2026
Osimertinib plus selumetinib in patients with EGFR-mutated advanced NSCLC with BRAF alterations post-progression on first-line osimertinib: ORCHARD
Zofia Piotrowska, Sarah B Goldberg, Jonathan W Goldman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 23, 2025
Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report
Xiuning Le, Christina Baik, Byoung Chul Cho, et al.
Cancer Discovery
|
October 1, 2013
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors
Nadine S Jahchan, Joel T Dudley, Pawel K Mazur, et al.
Page
of 14